{"id":"W4286295684","doi":"10.1200/jco.2022.40.16_suppl.tps9593","title":"A randomized, controlled, open-label, phase 2 study of cemiplimab ± RP1 in patients with advanced cutaneous squamous cell carcinoma (CERPASS).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Virus-based gene therapy research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":4,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"","keywords":"Medicine; Oncolytic virus; Nivolumab; Pembrolizumab; Radiation therapy; Phases of clinical research; Oncology; Internal medicine; Clinical trial; Dermatology; Immunotherapy; Cancer","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002096579,0.002195153,0.002745606,0.0005182536,0.0004207465,0.001132973,0.0008866438,0.001569449,0.009781932],"category_scores_gemma":[0.001480792,0.0008002315,0.00121491,0.0004364638,0.001028844,0.00132797,0.0004385574,0.002753564,0.001608427],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007073571,"about_ca_system_score_gemma":0.001524829,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005899244,"about_ca_topic_score_gemma":0.001444236,"domain_scores_codex":[0.9993344,0.0003335339,0.00002905573,0.0001460137,0.00004761729,0.0001093421],"domain_scores_gemma":[0.9991849,0.0001704503,0.0001910983,0.00006322029,0.00004806336,0.0003422637],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.958447,0.01904248,0.0008413192,0.0004436976,0.0004534806,0.00005923522,0.00005243718,0.0002604827,0.003501479,0.000088087,0.0008813919,0.01592889],"study_design_scores_gemma":[0.9109133,0.0869315,0.001057406,0.00001208772,0.0001290878,0.00002788626,0.00001404454,0.0001717889,0.0001873679,0.00005503842,0.0004931662,0.000007227868],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9751781,0.003420208,0.0009291783,0.0007865584,0.0006313662,0.01438172,0.001545698,0.0002403608,0.002886795],"genre_scores_gemma":[0.9695258,0.002466173,0.002691976,0.002039386,0.0007479024,0.01591493,0.001940185,0.00004566456,0.004627918],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.009781932,"threshold_uncertainty_score":0.03272378,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04996168488206171,"score_gpt":0.4272129769513422,"score_spread":0.3772512920692805,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}